Compare ITP & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITP | ONCO |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 2.8M |
| IPO Year | 2020 | 2021 |
| Metric | ITP | ONCO |
|---|---|---|
| Price | $0.15 | $0.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 216.2K | 183.7K |
| Earning Date | 05-12-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.01 | ★ 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $75,837,943.00 | $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.16 | $0.09 |
| 52 Week High | $0.39 | $6.73 |
| Indicator | ITP | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 38.26 | 36.66 |
| Support Level | N/A | $0.57 |
| Resistance Level | $0.20 | $1.01 |
| Average True Range (ATR) | 0.01 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 15.94 |
IT Tech Packaging Inc is a holding company engaged in the business of paper manufacturing in China. The company operates as a producer and distributor of paper products. It is involved in the production and distribution of three categories of paper products: packing paper (corrugating medium paper), offset printing paper, and tissue paper products. It also produces digital photo paper. Its business is structured into three segments: Dongfang Paper and Tengsheng Paper, which produce offset printing paper, corrugating medium paper, and tissue paper, and Baoding Shengde, which produces face masks and digital photo paper.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.